Compare Global X SuperDividend ETF (SDIV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs 10X Genomics Inc — how do they compare? Global X SuperDividend ETF trades at $24.98, while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| SDIV | TXG | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $67.29 |
52-Week Low | $22.90 | $11.34 |
Market Cap | — | $8.55B |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $25.07, down 0.16% with a bullish technical signal from moving averages. The ETF maintains a consistent $0.18 monthly dividend payment schedule through mid-2026, providing income stability. Recent news highlights SDIV's 9.29% yield and diversification benefits away from tech-heavy portfolios, though questions remain about dividend sustainability.
The outlook balances high income generation against sustainability concerns. Key opportunities include attractive yield in a low-rate environment and non-tech diversification, while risks center on dividend coverage and sensitivity to global economic conditions. Technical strength supports near-term stability.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
